A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age.

Author: Hiroaki IWAMOTO ¹ ; Kouji IZUMI ¹ ; Suguru KADOMOTO ¹ ; Tomoyuki MAKINO ¹ ; Renato NAITO ¹ ; Hiroshi YAEGASHI ¹ ; Kazuyoshi SHIGEHARA ¹ ; Yoshifumi KADONO ¹ ; Atsushi MIZOKAMI ¹
Author Information

1. Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8640, Japan.
Publication Type:Journal Article
Keywords: Gleason score; biopsy; elderly; percent free prostate-specific antigen; prostate cancer; prostate-specific antigen
From: Asian Journal of Andrology 2021;23(1):36-40
CountryChina
Language:English
Abstract: A standard modality for prostate cancer detection in men 75 years and older has not been established. A simple screening method for elderly patients is needed to avoid unnecessary biopsies and to effectively diagnose prostate cancer. A retrospective study was conducted on elderly patients who had prostate biopsy at Kanazawa University Hospital (Kanazawa, Japan) between 2000 and 2017. Of the 2251 patients who underwent prostate biopsy, 254 had clinically significant prostate cancer (CSPC) with a Gleason score (GS) of≥7 and 273 had a GS of <7 or no malignancy. In this study, patients aged 75 years or older were classified as elderly patients. GS ≥ 7 was characterized by a prostate-specific antigen (PSA) of the maximum area under the curve of 12 ng ml